Document:

exv10w1

Exhibit 10.1

	[ *** ]	 	 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT MARKED BY BRACKETS HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE
SECURITIES AND EXCHANGE ACT OF 1934 AS AMENDED.

Execution Copy

SETTLEMENT AGREEMENT

          This Settlement Agreement, dated as of July 23, 2010 (the “Effective Date”), is by and among
Purdue Pharma L.P., a Delaware limited partnership (“Purdue”), King Pharmaceuticals, Inc., a
Tennessee corporation (“KPI”), and Alpharma Inc., a Delaware corporation and a wholly-owned
subsidiary of KPI (“Alpharma” and, together with KPI, “King”). Purdue and King are sometimes
referred to herein individually as a “Party” and collectively as the “Parties.”

W I T N E S S E T H:

          WHEREAS, Purdue is the owner of United States patent number 6,696,088 (the “’088 Patent”) and
United States patent number 7,658,939 (the “’939 Patent”);

          WHEREAS, Purdue and King are involved in litigation, Civil Action No. 1:08 -cv- 50, (the
“Action”) in the United District Court for the Western District of Virginia (the “District Court”)
concerning, inter alia, the validity and infringement by King of the ’088 Patent and the ’939
Patent resulting from King’s having obtained approval from the United States Food and Drug
Administration (the “FDA”) for all dosage strengths of Embeda®, an extended release oral
formulation of morphine (the “Embeda® Products”) through its submission of New Drug Application
(“NDA”) No. 22-321 (collectively with all amendments and supplements thereto as of the Effective
Date, the “King NDA”) and subsequently selling the Embeda® Products;

          WHEREAS, in the Action, King has sought a declaratory judgment that its Embeda® Products do
not infringe the ’088 Patent or the ’939 Patent and that such patents are invalid, and Purdue has
asserted counterclaims against King that the Embeda® Products infringe one or more claims of the
’088 Patent and the ’939 Patent, and the Parties now seek to resolve these claims and counterclaims
without further litigation; and

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

 

 

          NOW THEREFORE, for good and valuable consideration, the sufficiency and receipt of which are
hereby acknowledged, the Parties agree as follows:

          1. (a) On the Effective Date, in addition to this Settlement Agreement, Purdue and King are
executing and delivering to each other the following documents:

                    (i) a Release by Purdue, in the form of Exhibit 1(a)(i) hereto (the “Purdue Release”); and

                    (ii) a Release by King, in the form of Exhibit 1(a)(ii) hereto (the “King Release”, and,
together with the Purdue Release, the “Releases”).

               (b) Unless otherwise expressly set forth herein, as used herein, the term “Settlement
Agreement” shall refer to this Settlement Agreement, and such Settlement Agreement, together with
each of the Exhibits attached hereto, shall be referred to as the “Settlement Documents.” The
definitions of the terms herein apply equally to the singular and plural of the terms defined.
Whenever the context may require, any pronoun will include the corresponding masculine, feminine
and neuter forms. The words “include”, “includes” and “including” will be deemed to be followed by
the phrase “without limitation”. Unless the context requires otherwise, (i) any definition of or
reference to any agreement, instrument or other document herein will be construed as referring to
such agreement, instrument or other document as from time to time amended, supplemented or
otherwise modified (subject to any restrictions on such amendments, supplements or modifications
set forth herein or therein), and (ii) the words “herein”, “hereof” and “hereunder”, and words of
similar import, will be construed to refer to this Settlement Agreement in its entirety and not to
any particular provision hereof. For purposes of the Settlement Documents, “Affiliate” means, as
to any Party, any person, firm, trust, partnership, corporation, company or other entity or
combination thereof, which directly or indirectly controls, is controlled by or is under common
control with such Party. The terms “control” and “controlled” mean ownership of fifty percent
(50%) or more, including ownership by trusts with substantially the same beneficial interests, of
the voting and equity rights of such person, firm, trust, partnership, corporation,

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

2

 

company or other entity or combination thereof or the power to direct the management of such
person, firm, trust, partnership, corporation, company or other entity or combination thereof.

          2. On the Effective Date, counsel for Purdue and counsel for King shall jointly inform the
District Court of the execution of this Settlement Agreement and, immediately after Purdue’s
receipt of the Settlement Payment, counsel for Purdue and counsel for King shall jointly file with
the District Court a stipulation dismissing the Action with prejudice. Such stipulation of
dismissal shall be in the form attached as Exhibit 2 hereto.

          3. Purdue covenants that neither it nor any of its Affiliates will sue, make, or assert
against King, its Affiliates, successors in interest, suppliers, contractors, subcontractors,
agents, wholesalers, retailers, customers, end users, manufacturers, or distributors (“King
parties”) any Claim for patent infringement of the  ́088 Patent, the  ́939 Patent or any other United
States patent owned by Purdue or any Purdue Affiliate, or for which Purdue or a Purdue Affiliate
has the right to grant a license, including without limitation, those patents and applications
listed in paragraph 5, that would be infringed, directly or indirectly, by one or more Embeda®
Products (collectively, the “Purdue Patents”) with respect to the manufacture, use, sale, offer for
sale or importation of the Embeda® Products (hereinafter, the “Covenant not to Sue”). This
Covenant not to Sue shall not apply to any patent outside the United States, provided that Purdue
shall obtain a limited covenant not to sue from its foreign Affiliates to permit King to
manufacture Embeda® outside of the United States solely for sale in the United States. This
Covenant not to Sue shall run with title to the Purdue Patents and shall bind any assignee or other
person or entity who acquires an interest in any of the Purdue Patents through assignment,
conveyance, grant or otherwise. Any assignment in any interest in any of the Purdue Patents shall
be subject to the terms of this paragraph 3. Purdue shall defend, indemnify, and hold King
harmless from and against any and all Claims arising from a breach of Purdue’s obligations in this
paragraph 3. King shall defend, indemnify and hold Purdue and its Affiliates harmless from any and
all claims arising in connection with King’s use of any Purdue Patent. King shall have no right to
enforce any Purdue Patent. This Covenant not to Sue shall not extend beyond the Embeda® Products.
As used herein, “Claim” means any claim, counterclaim, third party

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

3

 

claim, demand, action or cause of action for patent infringement. Purdue and King acknowledge
and agree that the execution of the Settlement Documents and the payment of the Settlement Payment
and/or Royalties set forth in paragraph 4, shall not be construed as an express or implied
admission of misconduct, responsibility, or liability whatsoever of either Party, and the Parties
expressly and specifically deny all such admissions. Rather, it is acknowledged and agreed that
the Settlement Documents have been entered into solely for the purpose of settling and compromising
the Action and to avoid the expense and uncertainty of continued litigation. Without limiting the
foregoing, no admission is made by King by execution of the Settlement Documents or by payment of
the Settlement Payment and/or Royalties as to (i) the validity or enforceability of any Purdue
Patent or of King’s alleged infringement thereof, or (ii) the appropriateness of any particular
royalty or other payment.

          4. (a) No later than ten (10) business days after the execution of this Settlement Agreement,
King will pay Purdue a one-time, non-refundable cash payment of [ *** ] United States dollars (US$
[ *** ]) (“Settlement Payment”) by wire transfer of immediately available funds to an account
previously designated in writing by Purdue. In addition, King will pay Purdue a non-refundable
royalty, quarterly in arrears at the end of each calendar quarter, equal to [ *** ] percent ([ ***
]) of the Net Sales of Embeda® Products during the applicable calendar quarter (the “Royalty”)
during the Royalty Term (defined below). Such Royalty will begin to accrue commencing August 1,
2010 and the first payment shall be due with respect to the period commencing August 1, 2010 and
ending on September 30, 2010 and quarterly thereafter. King shall pay such Royalty to Purdue by
wire transfer in immediately available funds, to an account previously designated in writing by
Purdue, within [ *** ] days following the end of each calendar quarter with respect to Net Sales
during the immediately preceding calendar quarter. King shall pay interest on any and all amounts
not paid when due hereunder at a rate equal to the lesser of (i) [ *** ] percent ([ *** ]) above
the prime rate reported in The Wall Street Journal (Eastern Edition) on the date such Royalty was
due, but not less than [ *** ] percent ([ *** ]), and (ii) the maximum permissible rate under the
law. Such interest shall accrue from the date such payment was originally due.

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

4

 

               (b) (i) The Royalty shall be payable for Net Sales made on or after August 1, 2010
until the
earlier to occur of (A) the expiration of all of the following: the ’088 Patent; the ’939 Patent;
and any patents claiming priority to United States patent application nos. 10/689,866 and
10/700,861 which issue before the later to expire of the ’088 Patent and the ’939 Patent and which
would be infringed by the Embeda® Products, and (B) the date on which, following the entry of a
judgment in another case or proceeding after the Effective Date, each and every asserted claim of
all of the following: the ’088 Patent and the ’939 Patent covering the Embeda® Products; and any
patents claiming priority to United States patent application nos. 10/689,866 and 10/700,861 which
issue before the later to expire of the ’088 Patent and the ’939 Patent and which would be
infringed by the Embeda® Products is held to be either (I) unenforceable or (II) invalid, or both;
provided, however, that in the case of either clause (I) or (II) above, the mandate affirming the
judgment in such other case or proceeding is issued by the United States Court of Appeals for the
Federal Circuit following appeal of such judgment, or the time for appeal from that judgment has
lapsed (the “Royalty Term”).

               (c) Each Royalty payment by King hereunder shall be accompanied by a royalty report from King
certified by an appropriate financial officer of King which sets forth (i) the Net Sales derived
from the sale of Embeda® Products, during the immediately preceding calendar quarter, and (ii) the
amount of the Royalty payable with respect to such Net Sales. If Purdue disputes the Net Sales
and/or Royalty amounts set forth in the royalty report, such dispute shall be resolved in
accordance with Section 4(e).

               (d) “Net Sales” shall mean the gross amount invoiced by King, or any licensee,
subcontractor
or agent of King, for the sale of the Embeda® Products in the United States, less the following
amounts directly attributable to Embeda® Products: (i) sales and excise taxes, value added taxes,
and duties which fall due as a direct consequence of such sales and any other governmental charges
imposed upon the importation, use or sale, but only to the extent that such taxes and duties are
(A) actually included and itemized in the gross amounts invoiced to and specifically paid by the
purchaser over and above the usual selling price, (B) not recovered or recoverable and (C) not
income or franchise

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

5

 

taxes or taxes in lieu thereof; (ii) trade, sales, trade show, quantity and cash discounts,
promotional discounts (e.g., co-pay cards) and stocking allowances; (iii) credits to customers for
purchaser returns, returned goods allowances, billing and shipping errors, recalls, rejected goods
and damaged goods; (iv) price adjustments, including those on customer inventories following price
changes; (v) allowances or credits to customers on account of withdrawal, recall, or return; (vi)
rebates, and wholesaler chargebacks or similar credits or payments granted to customers pursuant to
contract or otherwise (including any and all federal, state or local government rebates, discounts
or chargebacks, including Medicaid and Medicare rebates); (vii) freight, shipment and insurance
costs; and (viii) amounts paid pursuant to inventory management agreements. The amounts described
in clauses (i) through (viii) above shall be accrued in accordance with United States generally
accepted accounting principles consistently applied. Net Sales shall not include amounts invoiced
for the supply, disposition or use of Embeda® Products in clinical or pre-clinical trials or as
free samples (such samples to be in quantities common in the industry).

               (e) (i) Purdue shall have the right for a period of three years after receiving a royalty
report, and at its expense, to engage Deloitte & Touche Financial Advisory Services LLP, an
affiliate thereof, or another independent certified public accounting firm chosen by Purdue and
reasonably acceptable to King (a “CPA Firm”), to inspect and audit the relevant records of King
solely to verify the contents of the royalty report. King shall make its records available for
inspection and audit upon reasonable advance written notice during regular business hours at such
place or places where such records are customarily kept. Such inspection and audit right shall not
be exercised more than once in any calendar year. The results of each inspection, if any, shall be
provided to both Parties and shall be binding on all Parties unless King provides a written
objection to the inspection and audit findings within thirty days of receipt thereof. In the event
that any such inspection and audit shall conclude that the Royalty is understated by [ *** ]
percent ([ *** ]) or more in any given calendar year, King shall pay the reasonable fees of the CPA
Firm in respect of the inspection, and make any payments required to remedy the underpayment with
interest as provided herein. Any dispute regarding the results of any inspection and audit shall
be submitted to another independent certified public accounting firm acceptable to both

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

6

 

Purdue and King. The decision of such firm will be binding on the Parties, and the Party with
the least favorable outcome from such binding decision shall pay the fees and expenses of such
firm.

                    (ii) Prior to any inspection and audit taking place, the
independent certified public
accounting firm shall enter into a confidentiality agreement reasonably acceptable to King with
respect to the information to which they are given access.

          5. (a) King agrees that, except as provided in paragraphs 5(b), 5(c) and 5(d), it will not
initiate, file, participate, finance, aid, raise a defense or assist in any action or proceeding
before a court, agency, other tribunal or other governmental authority (except as required by court
order, subpoena or law, or in defending any claim of infringement) that challenges the validity,
patentability, priority of invention or other claim to priority or enforceability of the ’088
Patent, the ’939 Patent, any patents claiming priority to United States patent application nos.
10/689,866 and 10/700,861, or any of the following patents: U.S. Patent Nos. 6,277,384; 6,375,957;
6,475,494; 6,696,066; 7,172,767; 7,419,686; 6,228,863; and 6,627,635. The term “assist” shall mean
to provide any third party with King’s analysis of any of the patents identified above in this
paragraph 5(a) in furtherance of a validity challenge, provided that “assist” shall not include
providing or disclosing such analysis pursuant to the requirement of a governmental or judicial
agency, or in response to a subpoena or any discovery request made upon King, or if required by
operation of law. Nothing in this paragraph or elsewhere in this Settlement Agreement shall
preclude or prohibit any actions by King related to the prosecution of its patent applications.
King will not provide to any third party any Purdue confidential information, or attorney work
product relating to Purdue confidential information, except as required by statute, ordinance,
regulations, court order or compulsory legal process, provided that King will request confidential
treatment with respect to any confidential information or attorney work product disclosed pursuant
hereto.

               (b) With respect to King sequestered antagonist products other than Embeda® Products, King
will not be prohibited from taking any of the actions specified in paragraph 5(a)

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

7

 

on or after the date on which King files an NDA for such sequestered-antagonist product other
than an Embeda® Product.

               (c) King will not be prohibited from taking any of the actions specified in paragraph 5(a) if
Purdue or any assignee or Affiliate of Purdue breaches its obligations under paragraph 3.

               (d) King will not be prohibited from taking any of the actions specified in paragraph 5(a) if
Purdue or any of its Affiliates commences a patent infringement proceeding in the United States
against King alleging infringement of any patent specified in paragraph 5(a).

          6. Purdue represents and warrants as of the Effective Date that (a) it has all necessary power
and authority to execute and deliver the Settlement Documents and to perform its obligations
thereunder, (b) the execution, delivery and performance of the Settlement Documents have been duly
and validly authorized by it, (c) there is no other agreement, whether written or oral, among the
Parties hereto with respect to the subject matter of the Settlement Documents other than as set
forth herein and therein, (d) Purdue and/or one of its Affiliates owns the entire right, title and
interest in and to the Purdue Patents, including without limitation, U.S. Patent Nos. 6,696,088;
7,658,939; 6,277,384; 6,375,957; 6,475,494; 6,696,066; 7,172,767; 7,419,686; 6,228,863; and
6,627,635; no other person or entity has any rights under the Purdue Patents, and neither Purdue
nor any of its Affiliates has otherwise transferred or assigned any of its rights under the Purdue
Patents; (e) Purdue and/or one of its Affiliates has the sole right to enforce the Purdue Patents;
and (f) neither Purdue nor any of its Affiliates has transferred or assigned any of its rights or
claims with respect to the Action to a third party. Upon execution and delivery of the Settlement
Documents by Purdue, the Settlement Documents shall constitute the legal, valid and binding
agreements of Purdue, enforceable against it in accordance with their respective terms and
conditions, subject to bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting the enforceability of creditors’ rights generally and other general equitable principles
which may limit the right to obtain certain remedies.

          7. KPI and Alpharma represent and warrant as of the Effective Date that (a) each of them
has all necessary power and authority to execute and deliver the Settlement Documents and to

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

8

 

perform their obligations thereunder, (b) the execution, delivery and performance of the
Settlement Documents have been duly and validly authorized by each of them, (c) there is no other
agreement, whether written or oral, among the Parties hereto with respect to the subject matter of
the Settlement Documents other than as set forth herein and therein, (d) KPI or Alpharma owns all
right, title and interest in and to the King NDA, no other person or entity has any rights under
the King NDA, and neither KPI nor Alpharma has otherwise transferred or assigned any of its rights
under the King NDA subject to the lien of Credit Suisse AG as collateral agent pursuant to the
Credit Agreement dated as of May 11, 2010, among KPI and the lenders named therein and (e) neither
KPI nor Alpharma has transferred or assigned any of its rights or claims with respect to the
Action. Upon execution and delivery of the Settlement Documents by KPI and Alpharma, the
Settlement Documents shall constitute the legal, valid and binding agreements of each of them,
enforceable against each of them in accordance with their respective terms and conditions, subject
to bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the
enforceability of creditors’ rights generally and other general equitable principles which may
limit the right to obtain certain remedies.

          8. WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS SETTLEMENT AGREEMENT,
NEITHER PURDUE NOR ANY OF ITS AFFILIATES MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY
KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, INCLUDING WITH RESPECT TO THE PURDUE PATENTS
OR ANY OTHER PATENT HELD BY PURDUE. FURTHERMORE, UNLESS EXPRESSLY STATED IN THIS SETTLEMENT
AGREEMENT, NOTHING IN THIS SETTLEMENT AGREEMENT SHALL BE CONSTRUED AS A WARRANTY THAT ANY PATENT,
THE PRACTICE OF ANY INVENTION CLAIMED IN ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE
PURDUE PATENTS DO NOT, OR THE MAKING, HAVING MADE, USING, SELLING, OFFERING FOR SALE OR IMPORTING
OF EMBEDA® PRODUCTS BY ANY PERSON DOES NOT, INFRINGE ANY PATENT RIGHTS OR

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

9

 

OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. IT IS HEREBY AGREED AND ACKNOWLEDGED
BY KING THAT PURDUE IS GIVING NO GUARANTEE OR WARRANTY, EXPRESS OR IMPLIED, TO KING IN RELATION TO
THE SAFETY OR THERAPEUTIC EFFECTIVENESS OF THE EMBEDA® PRODUCTS OR THE VALIDITY OR ENFORCEABILITY
OF ANY INTELLECTUAL PROPERTY RIGHTS. FURTHER, KING WILL NOT GIVE ANY SUCH GUARANTEE OR WARRANTY TO
ANY THIRD PARTIES ON BEHALF OF PURDUE.

          9. Except as (a) required by statute, ordinance or regulation, including reporting
requirements under the Securities Exchange Act of 1934, as amended, (b) required pursuant to
compulsory legal process, (c) necessary for the exercise of the rights granted to the Parties under
the Settlement Documents, or (d) expressly permitted under this paragraph 9, none of Purdue, King,
or any of their respective Affiliates will publicly announce or otherwise disclose to any third
party any of the terms of the Settlement Documents, without the prior written approval of the other
Party, which prior written approval shall not be unreasonably withheld. Purdue acknowledges that
King reasonably expects to disclose certain information about the Settlement Documents (i) pursuant
to reporting requirements under the securities laws and regulations and (ii) to certain third
parties to the extent necessary to demonstrate the rights granted to King hereunder. To the extent
King determines to file this Settlement Agreement as part of its periodic reporting requirements,
it will redact the Settlement Payment and Royalty and request confidential treatment from the SEC
for such information. King will use commercially reasonable efforts to have such confidential
treatment granted. Other than as provided in the immediately preceding two sentences, if either
Party determines that it will be required to file the Settlement Documents to comply with legal or
regulatory requirements, promptly after the giving of notice by such Party as contemplated above,
the Parties will use commercially reasonable efforts to agree on those provisions of the Settlement
Documents that the Parties will seek to have redacted as provided above. Notwithstanding anything
to the contrary above, (i) Purdue may disclose the terms of the Settlement Documents to third
parties in connection with patent litigation involving the ’088 Patent, the ’939 Patent or the
other Purdue Patents or

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

10

 

in connection with settlement discussions and agreements with alleged infringers of ’088
Patent, the ’939 Patent or the other Purdue Patents, subject to all such third parties keeping the
terms of the Settlement Documents confidential, and (ii) each Party may disclose the terms of the
Settlement Documents to its respective Affiliates, insurers, lenders, attorneys and accountants,
subject to such Affiliates, insurers, lenders, attorneys and accountants being bound by
confidentiality obligations.

          10. (a) The Settlement Documents are binding upon and shall inure to the benefit of each Party
hereto, and each of their respective successors and permitted assigns. Except as provided in
paragraph 10(b), King may not assign, transfer, license or otherwise convey any of its rights or
obligations under the Settlement Documents without the prior written consent of Purdue, which
consent may be withheld in the sole discretion of Purdue. Any assignment or attempted assignment
of the rights hereunder by KPI or Alpharma in contravention of the provisions of this paragraph 10
shall be void and shall have no force or effect.

               (b) King may transfer or assign this Agreement, or any rights or obligations in this
Agreement, to (i) a third party that acquires (x) all or substantially all of the assets of King,
(y) the non-Embeda® sequestered antagonist products of King, or (z) the Embeda® Products, (ii) a
third party that is the surviving third party in a merger with King, (iii) a corporate successor in
interest of King, or (iv) an Affiliate of King; provided that in the case of an assignment
permitted by clause (b)(i)(y) or (b)(iv), King shall remain subject to the terms and conditions of
this Settlement Agreement.

               (c) Any party that becomes a transferee, assignee or successor in interest pursuant to
paragraphs 10(a) or 10(b) except for 10(b)(i)(y) of this Settlement Agreement, or obtains any
rights or obligations hereunder, as a result of any assignment or transfer, will thereby become
subject to all obligations and other applicable terms and conditions of this Settlement Agreement
and King will require that such party agree in writing to be bound by such obligations, terms and
conditions to the same extent as King had been bound. Any party that becomes a transferee,
assignee or successor in interest pursuant to paragraph 10(b)(i)(y) of this Settlement Agreement,
or obtains any rights or obligations hereunder, as a result of such assignment or transfer, will
thereby become subject to the applicable terms

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

11

 

and conditions of this Settlement Agreement (other than paragraphs 21 and 22), and King will
require that such party agree in writing to be bound by such obligations, terms and conditions to
the same extent as King had been bound.

          11. The Settlement Documents set forth the entire agreement and understanding among the
Parties hereto as to the subject matter hereof and supersede all other documents, oral consents or
understandings, if any, made between Purdue and King (excluding any agreements or stipulations
endorsed by court order) before the Effective Date with respect to the subject matter hereof. None
of the terms of the Settlement Documents shall be amended or modified except in a writing signed by
each of the Parties hereto. The Parties acknowledge that there have been a number of drafts of the
Settlement Documents exchanged between them prior to the Parties’ agreement on the final version of
the Settlement Documents which have been executed by them. The Parties expressly agree that these
drafts have been superseded by the executed Settlement Documents and shall not be used in any
dispute between the Parties as evidence with respect to interpreting the meaning of any provision
of this Settlement Agreement.

          12. Any term or provision of the Settlement Documents which is invalid or unenforceable in any
jurisdiction shall, as to that jurisdiction, be deemed reformed to the extent required to make such
term or provision valid or enforceable in the manner most closely reflecting the Parties’
intentions as reflected in the Settlement Documents (provided that any such reformation can be
achieved without material change to the economic value of the transactions contemplated by the
Settlement Documents), and shall not render invalid or unenforceable the remaining terms and
provisions of the Settlement Documents in such jurisdiction or in any other jurisdiction.

          13. This Settlement Agreement, and the rights and obligations created hereunder, shall be
governed by and interpreted according to the substantive laws of the State of New York without
regard to its choice of law or conflicts of law principles.

          14. Any notice required under this Settlement Agreement shall be in writing and shall be given
(and shall be deemed to be duly given upon receipt) by delivery in person, by facsimile or

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

12

 

by registered or certified mail (postage prepaid, return receipt requested) to the respective
Parties at the following addresses (or at such other address for a Party as shall be specified by
like notice):

	 	 	 

	 

	 	If to Purdue:
	 
	 	 
	 

	 	Purdue Pharma L.P.
	 

	 	One Stamford Forum
	 

	 	201 Tresser Boulevard
	 

	 	Stamford, CT 06901-3431
	 

	 	Attention: General Counsel
	 

	 	Fax No.: (203) 588-6272
	 
	 	 
	 

	 	with a copy to:
	 
	 	 
	 

	 	Chadbourne & Parke LLP
	 

	 	30 Rockefeller Plaza
	 

	 	New York, NY 10112
	 

	 	Attention: Stuart D. Baker
	 

	 	Fax No.: (212) 489-7130
	 
	 	 
	 

	 	If to King:
	 
	 	 
	 

	 	King Pharmaceuticals, Inc.
	 

	 	501 Fifth Street
	 

	 	Bristol, TN 37620
	 

	 	Attention: General Counsel
	 

	 	Telephone: (423) 989-8000
	 

	 	Fax No.: (423) 990-2566
	 
	 	 
	 

	 	with copies to:
	 
	 	 
	 

	 	King Pharmaceuticals, Inc.
	 

	 	400 Crossing Boulevard, 8th Floor
	 

	 	Bridgewater, New Jersey 08807
	 

	 	Attention: General Counsel
	 

	 	Telephone: (908) 429-6000
	 

	 	Fax No.: (908) 927-8430
	 
	 	 
	 

	 	Hunton & Williams, LLP
	 

	 	Attention: Thomas G. Slater
	 

	 	Riverfront Plaza, East Tower
	 

	 	951 East Byrd Street
	 

	 	Richmond, Virginia 23219
	 

	 	Telephone (804) 788-8200
	 

	 	Fax No. (804) 788-8218

          15. A waiver by any Party of any term or condition of this Settlement Agreement in any one
instance shall not be deemed or construed to be a waiver of such term or condition for any other

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

13

 

instance in the future (whether similar or dissimilar) or of any subsequent breach of this
Settlement Agreement. All rights, remedies, undertakings, obligations and agreements contained in
this Settlement Agreement shall be cumulative and none of them shall be a limitation of any other
remedy, right, undertaking, obligation or agreement of any of the Parties.

          16. Each of the Parties agrees that in executing the Settlement Documents and in accepting the
consideration provided for herein, each of the Parties does so with full knowledge of any and all
rights that each of the Parties may have with respect to the controversies herein compromised.
Each of the Parties affirms that it is not relying and has not relied upon any representation or
statement made by any of the other Parties with respect to the facts involved in said controversies
or with regard to each of the Parties’ legal rights or asserted legal rights, except as set forth
in paragraphs 6, 7 and 20 hereof. Each of the Parties hereby assumes the risk of any mistake of
fact or legal right with regard to said controversies or with regard to any of the facts or legal
rights that are now unknown to such Party, except with respect to any breach of paragraphs 6, 7 and
20 hereof.

          17. Each of the Parties agrees that it has received independent legal advice from its
attorneys with respect to the rights and asserted rights arising out of the controversies between
the Parties relating to the Action. Each of the Parties further agrees that it and its counsel
have had adequate opportunity to make whatever investigation or inquiry they may have deemed
necessary or desirable in connection with the subject matter of this Settlement Agreement, prior to
the execution hereof.

          18. This Settlement Agreement may be executed in counterparts (including by facsimile or other
electronic transmission), and each fully executed counterpart shall be deemed an original of this
Settlement Agreement.

          19. Except for the rights, agreements and covenants specifically granted pursuant to the
Settlement Documents, no other right, written or oral license, covenant not to sue, waiver or
release of future infringement or other written or oral authorization is or has been granted or
implied by the Settlement Documents. Furthermore, and for the avoidance of doubt, no activity by
King with respect to the making, having made, using, offering to sell, selling, shipping,
distributing or importing of any

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

14

 

pharmaceutical product or ingredient other than an Embeda® Product, shall constitute an
authorized sale under this Settlement Agreement.

          20. Purdue represents and warrants that it has no pending request for interference with
respect to Alpharma’s U.S. patent application Serial No. 10/667,676 and related applications and
covenants that it will not file any such request for so long as King does not challenge the
validity or enforceability of the ’088 Patent or the ’939 Patent. Nothing in this paragraph or
elsewhere in this Settlement Agreement shall preclude or prohibit any other actions by Purdue
related to the prosecution of its patents.

          21. Each of Purdue and King agrees with respect to any future litigation involving the ’088
Patent or the ’939 Patent to be bound by, and will jointly request that the District Court adopt,
the District Court’s June 22, 2010 findings in the Action with respect to the claim construction of
certain terms used in the ’088 Patent and the ’939 Patent. Notwithstanding the foregoing, either
Party may challenge such claim construction on an appeal from the District Court.

          22. Each of Purdue and King agrees that any future litigation between them with respect to the
’088 Patent and the ’939 Patent or any King sequestered-antagonist product will be brought in the [
*** ].

          23. King acknowledges that, as a result of this Settlement Agreement, there is no pending case
or controversy between the Parties with respect to infringement of the ’088 Patent or the ’939
Patent by the Embeda® Products. King will not assert the fact of this Settlement Agreement or the
existence of or settlement of the Action or the allegations included in paragraphs [ *** ] of the
Complaint, paragraphs [ *** ] of the Amended Complaint and paragraphs [ *** ] of the Supplemental
Complaint, in each case, filed in Civil Action 1:08-CV 00050 (U.S. District Court for the Western
District of Virginia) in support of a claim [ *** ] in any future litigation between the Parties.

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

15

 

[Remainder of this page intentionally left blank]

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.

16

 

Settlement Agreement Signature Page

          IN WITNESS WHEREOF, each of the Parties has caused this Settlement Agreement to be executed as
of the Effective Date by its duly authorized officer or agent.

	 	 	 	 	 
	 	PURDUE PHARMA L.P.

By: Purdue Pharma Inc., its general partner

 	 
	 	By:  	/s/ Edward B. Mahony
 	 
	 	 	Name:  	EDWARD B. MAHONY 	 
	 	 	Title:  	EVP, CFO AND TREASURER 	 
	 
	 	KING PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Brian A. Markison
 	 
	 	 	Name:  	Brian A. Markison 	 
	 	 	Title:  	President & Chief Executive Officer 	 
	 
	 	ALPHARMA INC.

 	 
	 	By:  	/s/ James W. Elrod
 	 
	 	 	Name:  	James W. Elrod 	 
	 	 	Title:  	General Counsel 	 
	 

 

			
	***	 	Confidential treatment requested pursuant to a request for
confidential treatment filed with the Securities and Exchange
Commission. Omitted portions have been filed separately with the
Commission.exv10wa

Exhibit 10(a)

September 8, 2010

Mr. Henry R. Bond

Dear Henry:

This letter will confirm our on-going conversations and serve as a revised offer of employment.

Your position of Senior Vice President and Chief Financial Officer will report directly to me and

is located in our Solon, Ohio facility. It is understood that you will work up to one day per week

out of our Alpharetta office.

As a member of the Management Committee, you will be eligible for the following compensation and
benefits:

	 	•	 	Starting base salary of $12,500, paid semi-monthly, as earned upon your start date,
annualized at $300,000. Your first merit increase consideration will occur April 1, 2011.
	 
	 	•	 	Annual target cash incentive of $150,000, effective at the start of FY11 which shall be
prorated for the portion of the year during which you are employed by Agilysys.
Achievement will be determined based on performance against the FY11 Annual Incentive Plan
(AIP) approved by the Board for Agilysys, Inc. executive officers, with MBO’s determined
after you begin at Agilysys as approved by the Compensation Committee of the Board of
Directors.
	 
	 	•	 	A grant of 30,000 shares of restricted stock to be made on your hire date.
	 
	 	•	 	A Long-Term Incentive Plan (LTIP) of 50,000 stock settled stock appreciation rights
(SSAR’s) to be made on your hire date.
	 
	 	•	 	A signing bonus of $75,000 payable on your date of hire that would be repaid to the
Company in full if you voluntarily terminate your employment with the Company prior to the
second anniversary of your date of hire, other than pursuant to Paragraph 5.E. of your
Employment Agreement, and a retention bonus of $75,000 payable on the second anniversary of
your date of hire, provided you are employed by the Company or its successor on that date.

 

 

Mr. Henry R. Bond

September 8, 2010

Page 2

	 	•	 	Twenty-five days per year of paid time off in addition to the Company’s holidays.
	 
	 	•	 	An Employment Agreement that contains a 12-month target compensation and benefit
continuation provision in the event of termination without cause and a non-competition
agreement covering the salary continuation period. A copy of the agreement is attached as
Exhibit A.
	 
	 	•	 	Full participation in the Agilysys, Inc. health, life insurance, paid time off (PTO),
401(K) and profit sharing plans. In addition, you will be eligible to participate in the
following executive benefit plans:

	 	 Ø	 	Benefit Equalization Plan (BEP)
	 
	 	 Ø	 	Executive Life Insurance Plan
	 
	 	 Ø	 	Personal Liability Policy
	 
	 	 Ø	 	Health Management Program
	 
	 	 Ø	 	Auto Allowance — $450 per month

	 	•	 	The Relocation Assistance benefits outlined in the Exhibit B.
	 
	 	•	 	This offer requires that you sign an Employment Agreement (non-competition), Insider
Trading Policy, Non-Disclosure Agreement and Business Ethics Policy. It also requires a
satisfactory background investigation and negative drug test to which you must consent.
Enclosed with this letter is the application for employment and consent forms that must be
completed and returned to me along with the directions and drug testing chain of custody
form.

Sincerely,

Martin F. Ellis

 

 

Exhibit A

EMPLOYMENT AGREEMENT

AGILYSYS, INC.

	 	 	 	 	 	 	 
	Employee Name: Henry R. Bond

	 	 	 	Position: Senior VP and CFO
	 
	 	 	 	 	 	 
	Effective Date: October 18, 2010
	 	 	 	 	 	 

You are a valuable Agilysys employee, and we expect you to make a significant contribution to
Agilysys’ success. As a result, Agilysys, Inc. (“Agilysys”) wishes to employ you during the
following years under the terms of this agreement.

	1.	 	Employment Period. You will be employed by Agilysys for the period
beginning with the Effective Date set forth above and ending with the
Termination Date as defined in Paragraph 5, below (the “Employment
Period”).
	 
	2.	 	Position. You shall initially be employed in the position set forth
above, with the duties and responsibilities customarily associated
with that position. From time to time, Agilysys may determine that it
is in Agilysys’ best interest to add to, subtract from, or otherwise
change your duties and responsibilities, or change or eliminate your
title.
	 
	3.	 	Best Efforts. You shall devote all of your business time and
attention to your duties as an employee of Agilysys. You shall use
your best efforts, energies, and skills to advance the business of
Agilysys, to further and improve its relations with suppliers,
customers and others, and to keep available to Agilysys the services
of its employees. You shall perform your duties in compliance with
all laws and Agilysys’ published policies, including ethical
standards set forth in the Code of Business Conduct.
	 
	4.	 	Compensation. Your compensation will be pursuant to Agilysys’
standard programs in effect from time to time. Agilysys reserves the
right, however, in its sole discretion, to impose salary reduction,
and/or other cost reduction programs, which may reduce your targeted
cash compensation (provided that any such program is not
discriminatory and treats you the same as other Agilysys employees
holding similar positions). You shall be eligible to participate in
any and all employee benefit plans made available from time to time
to Agilysys employees generally.
	 
	5.	 	Termination. Your employment may be terminated for Cause by Agilysys,
voluntarily by you, or without Cause by Agilysys. The last date of
your employment as a result of termination for any of these reasons
is the “Termination Date.”

	 	A.	 	Termination for Cause and
Voluntary Termination. If
your employment

 

 

	 	 	 	terminates
for any of the following
reasons: (a) your death,
disability, or legal
incompetence; (b) the
issuance by Agilysys of a
notice terminating your
employment “for Cause”
(which, for these purposes,
means: (i) breach of any
term of this agreement or
any other duty to Agilysys;
(ii) dishonesty, fraud, or
failure to abide by the
published ethical standards,
conflict of interest, or a
material breach of a policy
of Agilysys; (iii) your
conviction for any felony
crime, or for any other
crime involving
misappropriation of money or
other property of Agilysys;
(iv) misconduct, malfeasance
or insubordination; or
(v) gross failure to perform
under this agreement (not
including simply a failure
to attain quantitative
targets)); or (c) you
voluntarily resign your
employment, then your salary
will end on the Termination
Date.
	 
	 	B.	 	Termination Without Cause.
If your employment is
terminated by Agilysys for
any reason other than those
identified in
Paragraph 5.A., above, then
you will be paid a severance
(“Severance Payments”) equal
to one (1) year regular base
and target incentive salary
(if applicable), which will
be at the rate applicable to
you at the time your
employment terminates and
will be paid during regular
pay intervals during the one
(1) year period (“Severance
Period”). In case of
termination without Cause,
you will be eligible to
continue to participate in
applicable medical and
dental coverage program(s)
available to Agilysys
employees for the duration
of the Severance Period. You
will not otherwise be
eligible for severance under
any Agilysys severance plan
and you will not be eligible
to receive the Severance
Payments outlined in this
paragraph 5.B. more than
once.
	 
	 	C.	 	Change of Position. If
Agilysys changes your
position such that your
responsibilities or
compensation are
substantially lessened, or
if you are required to
relocate to a facility more
than 50 miles away from your
current locations (Cleveland
and Atlanta) (referred to
collectively as a “Change of
Position”), then you may,
within 30 days of such
Change of Position, give
Agilysys written notice that
you are terminating your
employment for this reason.
Such termination for Change
of Position will be deemed a
termination by Agilysys
without Cause for purposes
of this Agreement and you
shall be entitled to the
Severance Payments described
in Paragraph 5.B., above.
	 
	 	D.	 	Change of Control. If there
is a change of control of
Agilysys, as defined by
Section 409(A) of the
Internal Revenue Code, and
your employment with
Agilysys or its successor is
terminated without cause,
then you shall be entitled
to the Severance Payments
described in Paragraph 5.B.
above.
	 
	 	E.	 	Public Company Status. If
there is a change of control
of Agilysys and the Company
is no longer publicly
traded, then you shall be
provided with the
opportunity to terminate
your employment during the
thirty day period beginning
on the first anniversary of
delisting and receive the
Severance Payment described
in Paragraph 5.B. above

 

 

	6.	 	Confidential Information. During the course of your employment, you
have learned, and will learn, various proprietary or confidential
information of Agilysys and/or its related and affiliated companies
(including the identity of customers and employees; vendor
information; marketing information and strategies; sales training
techniques and programs; product development and design; acquisition
and divestiture opportunities and discussions; and data processing
and management information systems, programs, and practices). You
shall use such information only in connection with the performance of
your duties to Agilysys and agree not to copy, disclose, or otherwise
use such information or contest its confidential or proprietary
nature. You agree to return any and all written documents containing
such information to Agilysys upon termination of your employment.
	 
	7.	 	Restrictive Covenants.

	 	A.	 	No Hiring. During the
Employment Period and for
12 months thereafter, you
agree not to employ or
retain, have any other
person or firm employ or
retain, or otherwise
participate in the
employment or retention of
any person who was an
employee or consultant of
Agilysys at any time during
the 12 months preceding the
end of the Employment
Period.
	 
	 	B.	 	Non-Competition. In the
event that (i) Agilysys
terminates your employment
for Cause or (ii) you
voluntarily terminate your
employment with Agilysys for
any reason other than Change
of Position, you agree that
for a period of 12 months
after such termination you
will not be employed by,
own, manage, operate, or
control, or participate,
directly or indirectly, in
the ownership, management,
operation, or control of, or
be connected with (whether
as a director, officer,
employee, partner,
consultant, or otherwise),
any business which competes
with the business of
Agilysys, any peer group of
Agilysys identified in the
three prior proxy statements
of Agilysys, any Agilysys
customer, any vendor with
whom Agilysys does business
and any companies selling
enterprise computer systems,
and related consulting,
integration, maintenance and
professional services (the
“Non-compete Obligation.”)
	 
	 	C.	 	If Agilysys terminates your
employment for any reason
other than for Cause (or if
you terminate your
employment for reasons of
Change of Position), then
the above Non-Compete
Obligation will not apply to
you, unless Agilysys, at its
option, elects to extend the
Non-Compete Obligation to
you for up to a twelve-month
period (“Extended
Non-Competition Period”), in
which case Agilysys will pay
your regular base and target
incentive salary (if
applicable), in accordance
with regular payroll
practices (the
“Non-Competition Payments”),
during the Extended
Non-Compete Period.
	 
	 	 	 	Any Non-Competition Payments
made to you will be in lieu
of Severance Payments. To
the extent the
Non-Competition Period is
shorter than the Severance
Period applicable to you, if
any, Severance Payments, if
applicable to you, will be
made to you for the duration
of the remainder of the
Severance

 

 

	 	 	 	Period after the
end of the Non-Competition
Period. All decisions as to
(i) whether to extend to you
the Non-Compete Obligation
(and therefore, whether to
make Non-Competition
Payments to you); and
(ii) the duration of any
such Extended Non-Compete
Period, shall be within the
sole discretion of Agilysys,
and will be communicated to
you at the time of
termination. The
Non-Competition Payments
described in this
subparagraph apply only to
termination of your
employment by Agilysys for
reasons other than for
Cause, or if you terminate
your employment for reasons
of Change of Position.
	 
	 	 	 	It is understood and
acknowledged that any
Non-compete Obligation
arising under Paragraph 7
shall be in addition to any
other obligations on your
part under this Agreement,
including but not limited to
the confidentiality and
no-hiring provisions of
Paragraphs 7.A. and 7.B.,
above.

	8.	 	Assignment of Inventions. You agree to promptly and fully
disclose to Agilysys all ideas, inventions, discoveries,
creations, designs, and other technology and rights (and
any related improvements or modifications thereof),
whether or not protectable under any form of legal
protection afforded to intellectual property
(collectively, “Innovations”), relating to any activities
or proposed activities of the Agilysys and its
affiliates, conceived or developed by you during your
employment, whether or not conceived during regular
business hours. Such Innovations shall be the sole
property of Agilysys. To the extent possible, such
Innovations shall be considered a Work Made for Hire
under the U.S. Copyright Act. To the extent the
Innovations may not be considered such a Work Made for
Hire, you agree to automatically assign to Agilysys, at
the time of creation of such Innovations, any right,
title, or interest that you may have in such Innovations.
You further agree that you will execute such written
instruments, and perform any other tasks as may be
necessary in the opinion of Agilysys to obtain a patent,
register a copyright, or otherwise protect or enforce
Agilysys’ rights in such Innovations.
	 
	9.	 	Specific Performance and Injunctive Relief.
You acknowledge that Agilysys will be
irreparably damaged if the provisions of
this agreement are not specifically
enforced, that monetary damages will not
provide an adequate remedy to Agilysys, and
that Agilysys is entitled to an injunction
(preliminary, temporary, or final)
restraining any violation of this agreement
(without any bond or other security being
required), or any other appropriate decree
of specific performance. Such remedies are
not exclusive and shall be in addition to
any other remedy which Agilysys may have.

 

 

	10.	 	Severability and Reformation. The provisions of Paragraphs 6 through 10
of this agreement constitute independent and separable covenants which
shall survive termination or expiration of the Employment Period. Any
paragraph, phrase, or other provision of this agreement that is
determined by a court of competent jurisdiction to be overly broad in
scope, duration, or area of applicability or in conflict with any
applicable statute or rule shall be deemed, if possible, to be omitted
from this agreement. The invalidity of any portion hereof shall not
affect the validity of the remaining portions.
	 
	11.	 	Assignment.

	 	(a)	 	This agreement is personal to you, and cannot be assigned by
you to any other party.
	 
	 	(b)	 	This agreement shall inure to the benefit of, and be binding
upon and enforceable by Agilysys, and by its successors and
assigns. This agreement may be assigned by Agilysys, without
your consent, to a third party (“Assignee”) in connection with
the sale or transfer of all or substantially all of Agilysys’
business, or any division or unit thereof, whether by way of
sale of stock, sale of assets, merger or other transaction.
Such assignment by Agilysys will not constitute nor be deemed
a termination of your employment by Agilysys, and will not
give rise to any rights under Paragraph 5 of this Agreement.
After such assignment, any further rights which you have under
this Agreement will be the responsibility of the Assignee.

	12.	 	General. This agreement constitutes our full understanding relating to your
employment with Agilysys, and replaces and supersedes any and all agreements,
contracts, representations or understandings with respect to your employment
(collectively, “Prior Agreements”). This agreement is governed by and is to be
construed and enforced in accordance with the internal laws of the State of Ohio,
without giving effect to principles of conflicts of law. In the event of a conflict
between the terms hereof and the provisions of Agilysys’ Employee Handbook, the
terms hereof shall control; otherwise, the provisions of the Employee Handbook
shall remain applicable to your employment relationship. This agreement may not be
superseded, amended, or modified except in a writing signed by both parties.
	 
	 	 	In witness whereof the parties have executed this agreement this ___ day of
September, 2010.

	 	 	 	 	 
	 	AGILYSYS, INC.

 	 
	 	By:  	 	 
	 	 	Martin F. Ellis 	 
	 	Title:  	 	President and Chief Executive Officer 	 

 

 

	 	 	 	 	 
	 	 	 
	 	By:  	
 	 
	 	 	Henry R. Bond 	 
	 	Title:  	 	Senior Vice President and Chief
Financial Officer 	 
	 

 

 

Exhibit B

Henry Bond

Relocation Assistance

Agilysys will pay the following out-of-pocket expenses, supported by third-party receipts, in
connection with your relocation:

	 	•	 	The out-of-pocket costs incurred in connection with the moving of your primary
residence, including the shipment of household goods, packing and limited unpacking by
carrier, insurance coverage for household goods on an actual cash value basis, shipment of
one automobile, and travel expenses to the new residence
	 
	 	•	 	Weekly airfare for you between Cleveland and Atlanta until the later of July 15,
2011 or the date that Agilysys asks you to move your residence
	 
	 	•	 	Cost of up to three dinners per week while you are staying in Cleveland
	 
	 	•	 	Airfare for your spouse and two children to visit Cleveland, in lieu of your traveling
to Atlanta, up to five times between the your date of hire and July 15, 2011
	 
	 	•	 	Closing costs incurred on the sale of your current residence (including real estate
commissions) and closing costs on the purchase of a new home in Cleveland
	 
	 	•	 	Cost of temporary housing in Cleveland until the later of July 15th and the
date that Agilysys asks you to move your residence
	 
	 	•	 	Tax gross-up on the each of the above amounts which are compensatory to you
	 
	 	•	 	One month’s base salary, or $25,000, to cover incidental and miscellaneous moving
expenses incurred in connection with a relocation of your primary residence

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]